59 related articles for article (PubMed ID: 22913640)
1. Factors of influence on acute skin toxicity of breast cancer patients treated with standard three-dimensional conformal radiotherapy (3D-CRT) after breast conserving surgery (BCS).
Kraus-Tiefenbacher U; Sfintizky A; Welzel G; Simeonova A; Sperk E; Siebenlist K; Mai S; Wenz F
Radiat Oncol; 2012 Dec; 7():217. PubMed ID: 23249653
[TBL] [Abstract][Full Text] [Related]
2. Preliminary toxicity results using partial breast 3D-CRT with once daily hypo-fractionation and deep inspiratory breath hold.
Kowalchuk RO; Romano KD; Trifiletti DM; Dutta SW; Showalter TN; Morris MM
Radiat Oncol; 2018 Jul; 13(1):135. PubMed ID: 30053864
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Hypofractionated Whole Breast Irradiation (WBI) vs. Accelerated Partial Breast Irradiation (APBI) in Postmenopausal Women with Early Stage Breast Cancer: 5Years Update of the HYPAB Trial.
Lo Faro L; Fogliata A; Franceschini D; Spoto R; Dominici L; Bertolini A; Stefanini S; Vernier V; Ilieva MB; Scorsetti M
Clin Breast Cancer; 2024 Apr; 24(3):253-260. PubMed ID: 38220538
[TBL] [Abstract][Full Text] [Related]
4. Early and Intermediate Treatment Outcome After Postoperative External Beam Accelerated Partial Breast Irradiation in Patients With Early-Stage Breast Cancer.
Stenger-Weisser A; Unterkirhere O; Glanzmann C; Streller T; Logaritsch P; Studer G
Pract Radiat Oncol; 2024; 14(3):216-224. PubMed ID: 37925101
[TBL] [Abstract][Full Text] [Related]
5. Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort.
Hannoun-Levi JM; Gimeno Morales M; Gal J; Anchuelo J; Guinot JL; Gaztañaga M; Meszaros N; Polgar C; Strnad V; Schiappa R; Gutierrez C
Radiother Oncol; 2024 May; 194():110217. PubMed ID: 38460552
[TBL] [Abstract][Full Text] [Related]
6. Locoregional control and toxicity following high-dose hypofractionated and accelerated palliative radiotherapy regimens in breast cancer.
Webb K; Gothard L; Mohammed K; Kirby AM; Locke I; Somaiah N
Clin Oncol (R Coll Radiol); 2023 Sep; 35(9):e469-e477. PubMed ID: 37422360
[TBL] [Abstract][Full Text] [Related]
7. Partial-accelerated irradiation with stereotactic radiotherapy at a dose of 30 Gy in 5 fractions in early breast cancer.
Albendea Roch J; Anchuelo Latorre JT; Galdós Barroso MP; Navarrete Solano P; Rivero Pérez AL; Pinto Guevara F; García Lamela M; Olloqui Urroz J; Díaz de Tuesta M; Mazaira J; Muñoz P; Prada Gómez PJ
Clin Transl Oncol; 2024 Mar; ():. PubMed ID: 38506978
[TBL] [Abstract][Full Text] [Related]
8. Skin dose-volume predictors of moderate-severe late side effects after whole breast radiotherapy.
Cicchetti A; Mangili P; Fodor A; Gabellini MGU; Chiara A; Deantoni C; Mori M; Pasetti M; Palazzo G; Rancati T; Del Vecchio A; Gisella Di Muzio N; Fiorino C
Radiother Oncol; 2024 May; 194():110183. PubMed ID: 38423138
[TBL] [Abstract][Full Text] [Related]
9. Spectrophotometer and ultrasound evaluation of late toxicity following breast-cancer radiotherapy.
Yoshida EJ; Chen H; Torres MA; Curran WJ; Liu T
Med Phys; 2011 Oct; 38(10):5747-55. PubMed ID: 21992389
[TBL] [Abstract][Full Text] [Related]
10. Are We Missing Acute Toxicities Associated With Hypofractionated Breast Irradiation? A Report From a Large Multicenter Cohort Study.
Beydoun H; Griffith KA; Jagsi R; Burmeister JW; Moran JM; Vicini FA; Hayman JA; Paximadis P; Boike TP; Walker EM; Pierce LJ; Dominello MM;
Int J Radiat Oncol Biol Phys; 2024 Feb; ():. PubMed ID: 38364950
[TBL] [Abstract][Full Text] [Related]
11. Toward a Skin Dose-Area Metric Predictive of Moist Desquamation Using In Vivo Skin Dosimetry and Skin Assessments.
Malhotra A; Carpentier EE; Grahame S; Chan EK; Nichol A; Duzenli C
Adv Radiat Oncol; 2024 Jan; 9(1):101318. PubMed ID: 38260224
[TBL] [Abstract][Full Text] [Related]
12. Altered fractionation in radiation therapy for breast cancer in the elderly: are we moving forward?
Pinzi V; Fariselli L; Jereczek-Fossa BA
Transl Cancer Res; 2020 Jan; 9(Suppl 1):S217-S227. PubMed ID: 35117965
[TBL] [Abstract][Full Text] [Related]
13. The role of radiation therapy and systemic therapies in elderly with breast cancer.
Nardone V; Falivene S; Giugliano FM; Gaetano M; Giordano P; Muto M; Daniele B; Guida C
Transl Cancer Res; 2020 Jan; 9(Suppl 1):S97-S109. PubMed ID: 35117951
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of accelerated partial breast irradiation with volumetric-modulated arc therapy in elderly and frail patients.
Riou O; Fenoglietto P; Bourgier C; Lauche O; Boulbair F; Charissoux M; Ducteil A; Aillères N; Lemanski C; Azria D
Radiat Oncol; 2015 Oct; 10():209. PubMed ID: 26466672
[TBL] [Abstract][Full Text] [Related]
15. Accelerated partial breast irradiation with external beam three-dimensional conformal radiotherapy. Five-year results of a prospective phase II clinical study.
Mózsa E; Mészáros N; Major T; Fröhlich G; Stelczer G; Sulyok Z; Fodor J; Polgár C
Strahlenther Onkol; 2014 May; 190(5):444-50. PubMed ID: 24619017
[TBL] [Abstract][Full Text] [Related]
16. Decline of cosmetic outcomes following accelerated partial breast irradiation using intensity modulated radiation therapy: results of a single-institution prospective clinical trial.
Liss AL; Ben-David MA; Jagsi R; Hayman JA; Griffith KA; Moran JM; Marsh RB; Pierce LJ
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):96-102. PubMed ID: 24613813
[TBL] [Abstract][Full Text] [Related]
17. Current modalities of accelerated partial breast irradiation.
Cox JA; Swanson TA
Nat Rev Clin Oncol; 2013 Jun; 10(6):344-56. PubMed ID: 23629470
[TBL] [Abstract][Full Text] [Related]
18. Higher toxicity with 42 Gy in 10 fractions as a total dose for 3D-conformal accelerated partial breast irradiation: results from a dose escalation phase II trial.
Bourgier C; Acevedo-Henao C; Dunant A; Rossier C; Levy A; El Nemr M; Dumas I; Delaloge S; Mathieu MC; Garbay JR; Taghian A; Marsiglia H
Radiat Oncol; 2012 Aug; 7():141. PubMed ID: 22913640
[TBL] [Abstract][Full Text] [Related]
19. Early side effects of three-dimensional conformal external beam accelerated partial breast irradiation to a total dose of 40 Gy in one week (a phase II trial).
Bourgier C; Pichenot C; Verstraet R; El Nemr M; Heymann S; Biron B; Delaloge S; Mathieu MC; Garbay JR; Bourhis J; Taghian AG; Marsiglia H
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1228-35. PubMed ID: 20932662
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
